You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Implementation and validation of a lung x-ray interferometry imaging system, with applications to COPD, COVID-19 and other lung diseases
SBC: REFINED IMAGING, LLC Topic: NHLBIAbstractLung diseases ranging from cancer to chronic obstructive pulmonary disease (COPD) affect large numbers of men and women worldwide each year. Current news reports describe the respiratory impact of COVID-19; likewise, the past year has seen extensive coverage of the respiratory problems caused by vaping. Worldwide, lung diseases of all types result in millions of deaths per year at a stagge ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease
SBC: Oleolive, Inc. Topic: NIASUMMARY Alzheimer’s disease (AD) and related dementias are devastating conditions that affect millions of people, but no effective treatment options exist. Studies are currently being performed as part of the funded Phase II STTR parent award to test efficacy of a potential AD therapeutic, OL-003, in two additional animal models and assess pharmacology and toxicology. The overarching goal of the ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Chemosensitization of Glioblastoma by Propentofylline
SBC: Oleolive, Inc. Topic: 102SUMMARY Glioblastoma (GBM) is the most common primary tumor of the CNS with limited treatment options and a poor clinical prognosis. Standard of care treatment, including surgical resection, radiation therapy and concurrent temozolomide (TMZ) treatment followed by adjuvant TMZ, produces a median survival in newly diagnosed GBM of ~15 months. Tumor recurrence happens due to therapy resistant tumor ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
New anti-glioblastoma metabolic compounds with high potential for Blood Brain Barrier penetration
SBC: WAYPATH PHARMA LLC Topic: NCIGlioblastomas are very aggressive tumors of the central nervous system (CNS) with a median patient survival of about 16 months. Therapeutic options for glioblastoma patients are very limited mostly because the majority of potential anti-cancer drugs do not cross the blood brain barrier (BBB). In addition, recently tested immunotherapies including immune checkpoint inhibitors, tumor vaccines, and a ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
PHMB-Impregnated Acellular Biologic Grafts for Treatment of Third-Degree Burns
SBC: BioAesthetics Corporation Topic: 300PROJECT SUMMARY BioAesthetics is developing a novel acellular graft for improved burn wound healing. Our patent- pending drug-loaded, polymer-integrated acellular biologic graft (PCT/US19/25306) will act as a barrier to pathogens, deliver anti-infectives to the wound site during healing, and provide an optimal regenerative scaffold. This will allow for a single-stage wound reconstruction, without ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Novel non-narcotic analgesic for acute and chronic pain
SBC: South Rampart Pharma, LLC Topic: 104Abstract Acute and chronic pain affect more than 50 million Americans and there is an enormous unmet need for safer pain relief. Although acetaminophen (ApAP) is among the medicines most commonly used for pain relief, hepatotoxicity is a risk and overdose is the most common cause of acute fulminant hepatic failure. Oxidation of ApAP to N-acetyl-p-benzoquinone imine (NAPQI) leads to hepatotoxicity. ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Intelligent Sensor Systems- 2020
SBC: SEV1TECH, LLC Topic: T13Testing of rocket engines requires an extensive instrumentation of the article under test in order to collect data on the performance of various aspects of the engine.nbsp; Currently these sensors require extensive wiring both on the test article and within the test stand in order to connect the sensors to the data acquisition equipment.nbsp; This instrumentation is complex, often including severa ...
STTR Phase I 2020 National Aeronautics and Space Administration -
Oleocanthal functional food products for breast cancer recurrence control
SBC: Oleolive, Inc. Topic: 102SUMMARY From Parent Grant (R41CA247025) Triple negative breast cancer (TNBC) represents 20% of the breast cancer (BC) cases in the US. TNBC patients have a poor recurrence-free, overall survival rate, and limited available treatment options. The Mediterranean olive oil-rich diet is documented to reduce BC incidence. (-)-Oleocanthal (OC) is a natural phenolic secoiridoid exclusively occurring in ex ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Novel non-narcotic analgesic for acute and chronic pain
SBC: South Rampart Pharma, LLC Topic: 104Abstract Acute and chronic pain affect more than 50 million Americans and there is an enormous unmet need for safer pain relief. Although acetaminophen (ApAP) is among the medicines most commonly used for pain relief, hepatotoxicity is a risk and overdose is the most common cause of acute fulminant hepatic failure. Oxidation of ApAP to N-acetyl-p-benzoquinone imine (NAPQI) leads to hepatotoxicity. ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Noninvasive biomarkers for gastrointestinal disease in preterm infants
SBC: CHOSEN DIAGNOSTICS INC Topic: NICHDThe goal and significance of this project is to develop a clinically usable diagnostic test for gastrointestinal disease and to reduce healthcare costsNecrotizing enterocolitisNECis the most frequent and lethal gastrointestinal disease for preterm infantsIt affects newborns at a rate ofperUS births per year and has an average total in hospital treatment cost of $per patientAlthough first described ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health